Valuation: Actinogen Medical Limited

Market Cap 173M 117M 106M 98.13M 88.64M 167M 10.98B 1.18B 468M 5.89B 439M 429M 18.66B P/E 2027 *
-
P/E 2028 * -
Enterprise Value 173M 117M 106M 98.13M 88.64M 167M 10.98B 1.18B 468M 5.89B 439M 429M 18.66B EV / Sales 2027 *
4.5x
EV / Sales 2028 * -
Free-Float
81.27%
Yield 2027 *
-
Yield 2028 * -
10-29 Actinogen Medical Targets Mid-November for Alzheimer's Trial Results Release MT
10-28 Actinogen Medical Limited Achieves Database Lock In Pivotal XanaMIA Trial Of Oral Xanamem In Alzheimer?s Disease And Narrows Guidance For Final Topline Trial Results To Mid-November CI
09-23 Actinogen Medical Limited Completes Final Participant Visit for Xanamia Phase 2B/3 Alzheimer?S Disease Clinical Trial CI
09-23 Actinogen Medical Completes Final Patient Visit in Alzheimer's Therapy Trial; Shares Up 5% MT
09-01 Actinogen Medical Limited - Special Call
08-27 Actinogen Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2026 CI
08-06 Actinogen Medical Advances Oral Enzyme Inhibitor for Potential Alzheimer's Disease Treatment MT
07-20 Actinogen Medical Announces Results from Xanamem Phase 2 Depression Proof-Of-Concept Trial CI
07-20 Actinogen Says Results from Phase Two Trial of Therapy Candidate in Patients with Major Depressive Disorder, Cognitive Impairment Published MT
06-18 Actinogen Medical Receives Independent DMC Positive Recommendation for Phase 2b/3 Alzheimer's Disease Trial, Shares Jump 10% MT
05-28 Actinogen Medical Limited Announces Positive EMA Scientific Advice and Provides Update on Xanamem Alzheimer?s Disease Program CI
05-28 Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program MT
04-02 Actinogen Medical Launches Buy-Back Under New Employee Share Scheme; Shares Fall 3% MT

Last Transcript: Actinogen Medical Limited

1 day-4.26%
1 week-6.25%
Current month+7.14%
3 months-1.10%
6 months+9.76%
Current year-26.23%
1 week 0.04
Extreme 0.045
0.05
1 month 0.04
Extreme 0.039
0.05
Current year 0.03
Extreme 0.031
0.07
1 year 0.03
Extreme 0.031
0.07
3 years 0.02
Extreme 0.019
0.1
5 years 0.01
Extreme 0.014999
0.18
10 years 0.01
Extreme 0.007
0.2
Manager TitleAgeSince
Chief Executive Officer 66 15/03/2021
Director of Finance/CFO - 05/02/2024
Chief Tech/Sci/R&D Officer 73 01/02/2023
Director TitleAgeSince
Director/Board Member 75 01/12/2017
Chairman 70 01/03/2017
Director/Board Member 70 04/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Exercice

Founder

-237,029 0.0063%
09/09/26 Exercice

Founder

237,029 0.0063%
28/08/26 Exercice

Founder

-275,331 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
-4.26%-6.25%-13.46%+104.55% 117M
-1.29%-3.91%+51.98%+69.06% 65.56B
-2.64%-1.13%+7.82%+88.90% 60.41B
-0.75%+0.76%+23.47%+87.61% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
-1.59%-2.90%+76.01%+56.83% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -1.34%-1.01%+30.30%+168.79% 41B
Weighted average by Cap. -1.16%-1.58%+34.53%+149.95%

Financials

2027 *2028 *
Net sales 38.5M 25.99M 23.61M 21.82M 19.71M 37.19M 2.44B 262M 104M 1.31B 97.53M 95.47M 4.15B -
Net income -700K -473K -429K -397K -358K -676K -44.37M -4.77M -1.89M -23.81M -1.77M -1.74M -75.43M -49.6M -33.49M -30.42M -28.11M -25.39M -47.91M -3.14B -338M -134M -1.69B -126M -123M -5.34B
Net Debt - -
Projected Income Statement - Annual - Actinogen Medical Limited
Logo Actinogen Medical Limited
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism is to control elevated levels of cortisol (stress hormone) in the brain through the inhibition of the cortisol synthesis enzyme, 11B-HSD1, without affecting production of cortisol by the adrenal glands, which is essential for the body’s normal functioning. Xanamem is a once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex.
Employees
6
Date Price Change Volume
12/11/26 A$0.0450 -4.26% 8,468,087
11/11/26 A$0.0470 -2.08% 5,648,328
10/11/26 A$0.0480 0.00% 7,712,803
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.0450AUD
Average target price
0.0800AUD
Spread / Average Target
+77.78%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Actinogen Medical Limited